Madrid, Spain
10 – 11 Feb 2026
Operationalizing AI: Turning proven AI use cases into everyday practice across life sciences.
SVP, Head of Regulatory Affairs and PV Operations
Astellas
SVP, Worldwide Patient Safety Officer
Bristol Myers Squibb
“The most competitive pharma companies in the coming decade will be masters of data and digital technologies.” So begins the June 2017 industry brief, “Reinventing the Role of Medical Affairs,” by Bain & Company.
From reporting challenges to data integration and data silos with ...
As different regulatory authorities have different timelines for adoption of these standards, E2B(R2) E2B(R3) will have to coexist. But having to operate two solutions creates huge complexities, unless you find a solution compliant with both. ArisGlobal LifeSphere Safety MultiVigilance is the only drug safety database solution provider thus far to provide full compliance to E2B R2 and E2B R3 standards for both import and export.
Artificial intelligence (AI), machine learning, deep learning, natural language processing ...
Silos have long plagued the life sciences industry, and nowhere ...
Today’s Medical Information (MI) and Medical Affairs professionals are juggling ...
Safety departments at Marketing Authorization Holders & Regulatory Authorities are ...
Rising Expectations from Regulatory Affairs Executives As we all know ...
Artificial intelligence (AI), machine learning, deep learning, natural language processing – in short, cognitive computing, is changing the pharmacovigilance world as we know it. While there’s a lot of talk about how AI will affect jobs, where it will have the most powerful impact is on the quality of work and the speed at which manual tasks can be accomplished.
This is the last in the ArisGlobal three-part blog series on Regulatory Affairs transformation. Digitization is sweeping the life sciences industry, disrupting traditional working practices and opening doors to better ways of collaborating, tracking and sharing documents and data, and gaining clear oversight into the product supply chain.
ArisGlobal is a pivotal partner in the life sciences industry, specializing in solutions that drive drug development, safety monitoring, and regulatory compliance. We collaborate with more than 220 global life sciences companies, CROs, and government health authorities, including leading biopharmaceutical firms and regulatory bodies such as FDA, Health Canada, and NMPA.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.
Quick Links
© 2024 ArisGlobal – All Rights Reserved
